menu
    • menu

    Company profile for Kedrion

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Kedrion SpA (“Kedrion”) is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, Primary Immune Deficiency and Rh sensitization which can lead to hemolytic disease of the fetus and newborn.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    KedrionUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Kelby Street 11th Floor Fort Lee, NJ 07024
    Telephone
    Telephone
    1-201-242-8900
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kedrion.us/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EMA Grants Orphan Status To Kedrion's Aceruloplasminemia
    EMA Grants Orphan Status To Kedrion's Aceruloplasminemia

    27 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-27/european-medicines-agency-ema-grants-orphan-drug-designation-to-kedrions-plasma-derived-treatment-for-congenital-aceruloplasminemia-a-rare-genetic

    PHARMIWEB
    27 Nov 2025
    Share Share
    Advanced Infusion Care (AIC) Adds YIMMUGO® By Kedrion Biopharma
    Advanced Infusion Care (AIC) Adds YIMMUGO® By Kedrion Biopharma

    20 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251020834522/en/Advanced-Infusion-Care-AIC-Now-Offers-Kedrion-Biopharmas-YIMMUGO-Immune-Globulin-Intravenous-Human-Dira-10-Liquid

    BUSINESSWIRE
    20 Oct 2025
    Share Share
    kedrion Biopharma's Yimmugo Now Available in The U.S
    kedrion Biopharma's Yimmugo Now Available in The U.S

    09 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/yimmugo-now-available-in-the-us-kedrion-biopharma-commercializes-a-new-ig-therapy-for-pi-302580013.html

    PR NEWSWIRE
    09 Oct 2025
    Share Share
    Kedrion Bio Gets FDA Nod For Qivigy® In Primary Immunodeficiency
    Kedrion Bio Gets FDA Nod For Qivigy® In Primary Immunodeficiency

    29 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kedrion-biopharma-receives-fda-approval-for-qivigy-immune-globulin-10-iv-for-treatment-of-primary-humoral-immunodeficiency-in-adults-and-confirms-its-plan-to-increase-investments-in-the-us-throughout-its-global-operations-302569407.html

    PR NEWSWIRE
    29 Sep 2025
    Share Share
    Kedrion COAGADEX Gets Orphan Drug Status for aFXD, Begins Trial
    Kedrion COAGADEX Gets Orphan Drug Status for aFXD, Begins Trial

    29 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kedrion-biopharma-receives-orphan-drug-designation-for-coagadex-for-acquired-factor-x-deficiency-afxd-and-starts-clinical-trial-to-evaluate-efficacy-and-safety-302516604.html

    PR NEWSWIRE
    29 Jul 2025
    Share Share
    Kedrion Raises Awareness Around Plasminogen Deficiency
    Kedrion Raises Awareness Around Plasminogen Deficiency

    05 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kedrion-raises-awareness-around-plasminogen-deficiency-302446674.html

    PR NEWSWIRE
    05 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search